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Dr Stephen Fremes (Toronto, Canada). I wish to thank the
authors for providing me with a copy of the manuscript and the
presentation in advance.
The authors have performed a single-center observational study
to evaluate whether the benefits observed with the use of radial
grafting are evident across the spectrum of patient age. Conduit
selection was according to the decision of the consultant. Late
survival from the national registry was the primary study end
point. The authors used complex, appropriate, and sophisticated
statistical analysis to minimize bias inherent in the data. The
average follow-up was 5.7 years in the propensity-matched
populations. The investigators demonstrated that there was an
overall survival advantage with radial grafting; however, this
benefit in survival was only evident in patients younger than
70 years.
There are conflicting data in the literature regarding the
appropriateness or added value of increased arterial revasculariza-
tion in older patients, and this applies to both the use of radial
arteries as well as bilateral mammary arteries. I have several
questions which I will ask one at a time.
First of all, there were over 16,000 patients initially undergoing
isolated coronary surgery at Papworth over 16 years; however, the
study population consisted of 9000 patients, and there were more
than 4000 excluded because of information lacking on the choice
of arterial conduit. So, do you think that this would differentially
affect the results of your study one way or the other?1084 The Journal of Thoracic and Cardiovascular SurDr Benedetto. Thank you for your question. The number of
missing data was equally distributed over across all study periods.
We did assess the impact of missing data on outcomes by
conducting a simple analysis on the rate of late mortality in
patients with missing data, and we found no differences between
patients with missing data and patients included in the final
analysis. This was the only tool that we had to confirm that our
conclusions are reliable, even if it is a high number of patients
with missing data. However, the final sample study is large and
allowed us to reach reliable conclusions.
Dr Fremes. Thank you. One of the potential explanations for
the observed results is bias in the selection of the second arterial
conduit by the consultant surgeon. In other words, the radial artery
may have been preferentially used in younger patients, who are
excellent revascularization candidates, but restricted in older
patients, unless there were no other options. Do the authors believe
this or other sources of bias may have explained the lack of benefit
in older patients?
Dr Benedetto. Excellent question, thank you. The nonparsimo-
nious, saturated, propensity matching used in this study tried to
minimize the effects of selection and treatment bias, a limitation
inherent in any retrospective analysis. Furthermore, it is unlikely
that surgeon’s choice of conduits may have been forced by lack
of venous conduits, as most patients received saphenous vein
grafts in addition to the radial artery graft.
We also investigated the effect of the surgeon’s experience, the
surgeon effect on the final estimates of effect of radial artery use,
but we did not find a significant effect of surgeon on late survival.
In view of the high number of surgeons involved in this analysis,
we decided to adjust it not for a single surgeon but for the year
of operation, because we found a significant relationship with
between operative mortality and year of operation. Over time,
we found a decreasing operative mortality rate. This was also
adjusted for surgeon’s experience.
Dr Fremes. A potential explanation is the notion of
competing risk, and I assume this is what you assume explains
the lack of benefit. In other words, as patients age, the risk
of death from noncardiac causes increases. So one way to
illustrate this would be to examine the cause of death in these
patients and to see if, in fact, they are dying from noncardiac
causes. Do the authors plan to examine cause-specific mortality
in these patients?
Dr Benedetto.When we investigated our data set, we observed
that we did not have reliable information about specific cause of
death, and we decided to conduct this analysis on all-cause
mortality. We are going to complete our data set, going through
the notes, and try to obtain a more complete data set, which will
include specific cause of death. However, we decided to use
all-cause mortality as the primary outcome measure for this
analysis because it is well known that all-cause death is the most
robust and unbiased index to investigate the effect of a treatment
in a retrospective study. So, we are confident that all-cause
mortality in this retrospective analysis is a more reliable index
than cardiac-specific mortality to investigate the effect of an
arterial conduit.
However, we agree with your point and we intend to complete
our data set, going through the notes to try and obtain reliable
information on specific causes of death.gery c November 2013
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DDr Fremes. Two more questions. One potential explanation
that the radial artery may be a worse conduit in older patients
compared to younger patients is perhaps due to thickening of the
radial artery or plaque. In our institution, we actually screen
older patients with a duplex scan to look for irregularities of
the radial artery as well as assessing the adequacy of ulnar
collateral circulation. What is the screening process at Papworth?
Dr Benedetto. It was mostly the Allen test before surgery, and
intraoperatively before harvesting the radial artery, we assessed the
finger saturation during temporary occlusion of the radial artery, to
confirm the finding of the Allen test. We did not conduct any
ultrasound duplex scans of the radial artery before surgery. It is
possible and reasonable that atherosclerosis of the radial artery
in patients beyond 70 years of age may be one of the causes that
affects the survival benefit from this conduit in elderly.
Dr Fremes. Lastly, based on the findings of our study, what do
the surgeons at Papworth recommend in terms of conduit selection
for their older patients?
I wish to thank the AATS for the privilege to discuss this
excellent and provocative paper.
Dr Benedetto. It is difficult to change an individual’s belief
about the choice of graft, because at the moment we have no
definitive evidence or recommendations to guide choice of grafts
other than the LITA to complete surgical revascularization.
I hope that, on the basis of these data, surgeons would consider
arterial grafts more often to complete surgical revascularization
than they do at present.
Dr Philip Hayward (Melbourne, Australia). Thank you for a
very nice talk. As you know, our randomized trial that you quoted
in your meta-analysis has not shown any survival advantage yet,
only at midterm follow-up. But I just wanted to agreewith a couple
of things that Steve Fremes said.
Analysis of the Melbourne-based database of Brian Buxton and
colleagues, with about 10,000 patients, has focused on total
arterial revascularization versus mixed grafts. We have found
differently from you, with a survival advantage in the total arterial
group which was not age dependent. However, as you suggest and
in our data set, this probably does not apply in peripheral vascular
disease. It does relate to radial quality, as Steve Fremes said, with
patients in peripheral vascular disease having probably poor
quality radials, and I suspect the older patients with peripheral
vascular disease are dying of other causes, which is why there is
no benefit.
But a nice talk, and wewill discuss it again when we finalize our
data.
Dr Benedetto. Thank you for your question. A recent paper
reporting outcomes of radial artery use in the elderly concluded
that it may be advantageous to use it even in such patients.
However, looking at the survival curves, we found that the main
difference in survival between the 2 groups is to be found inThe Journal of Thoracic and Caryounger patients. In turn, this raises a concern about the surgical
profile of patients receiving radial artery versus saphenous vein,
because the main difference in mortality is related to the younger
age at the time of surgery. So, I think that we need to conduct
robust and reliable adjusting in a retrospective analysis to be
sure that we are looking at the same main population. In a
retrospective analysis, it is generally difficult to adjust for all
factors that may affect the outcome measures under consideration,
because patients receiving radial artery may be different from
patients receiving only saphenous vein grafts. Therefore, it is
possible that some of the discordant conclusions you are referring
to may be related to selection bias.
Dr Codispoti. As the senior author on Dr Benedetto’s paper,
I rise to complete the answer to Dr Fremes’ insightful question,
related to what are the current recommendations and practice
in Papworth, in light of these data. The search for an answer to
the question of which patient is more likely to benefit from
use of the radial artery is exactly the reason why we wanted
to conduct this analysis, and we obviously stand by the solidity
of its results. Based on this, we will adopt a more coherent
strategy towards choice of the radial artery and more in general
of arterial grafts in patients younger than 70 years. We look
forward to seeing Phil Hayward’s and the Melbourne group’s
results next year.
Dr Pieter Kappetein (Rotterdam, The Netherlands). You pro-
pose a randomized trial as one of your last points in your conclu-
sion slide. If we look at the trial from David Taggart, who is
randomizing patients with 2 mammary arteries versus 1 mammary
artery, 16% of those patients that were randomized with 2 mam-
mary arteries only got 1 mammary artery graft. So, there were a
lot of crossovers, which underpowers his study tremendously.
The only thing to overcome that is to analyze it as an as-treated
population. What would be your recommendation? How would
you design a randomized trial to show that a radial artery is better
than a saphenous vein graft?
Dr Benedetto. This is a pertinent question, to which there is no
easy answer. I think that before producing a new randomized
control trial comparing the saphenous vein graft with an arterial
graft, we need to understand better and investigate the causes for
differences observed in previous randomized controlled trials
using similar outcome measures. I believe that many of the
different conclusions in respect to similar outcome measures
reached in previous trials are due to differences in their study
design. It is also possible that the different conclusions reached
by studies on similar patient populations using the same outcome
measures may be related to surgeons’ experience, or perioperative
management with calcium antagonists. Therefore, before we start
another randomized controlled trial, I think we need to better
understand why we have different conclusions from previous
randomized studies.diovascular Surgery c Volume 146, Number 5 1085
